Antibody-drug Conjugates

ADC Technology Report: Prospects for Next-Generation ADC Development

by
ADC Technology Report: Prospects for Next-Generation ADC Development

Antibody-drug conjugates (ADCs) have become a popular avenue for cancer treatment in recent years. They typically consist of monoclonal antibodies (mAbs) covalently linked to cytotoxic drugs (payloads) through chemically synthesized linkers. ADCs combine the advantages of high specificity targeting and effective killing action, achieving precise and efficient elimination of cancer cells. Figure 1. Structure and … Read more

Introduction to Antibody-Drug Conjugates (ADC)

by
Introduction to Antibody-Drug Conjugates (ADC)

Since the first use of cytotoxic chemicals to treat cancer, oncologists have been searching for ways to improve efficacy without significantly increasing overall toxicity to patients. One of the methods attempted to enhance the killing effect on tumor cells is the use of cytotoxic agents with potency at picomolar or lower levels (such as microtubule … Read more

Design Mechanisms and Adverse Reaction Management of Antibody-Drug Conjugates (ADCs)

by
Design Mechanisms and Adverse Reaction Management of Antibody-Drug Conjugates (ADCs)

Introduction: Antibody-drug conjugates (ADC) consist of antibodies, linkers, and small molecule cytotoxic drugs, combining high specificity and high cytotoxicity advantages. However, their structural diversity and complexity, along with the low content of released small molecule toxins in the circulatory system, pose significant challenges for pharmacokinetic studies. This article will discuss the mechanisms, design, safety features, … Read more

Comprehensive Analysis of Antibody-Drug Conjugate (ADC) Technology

by
Comprehensive Analysis of Antibody-Drug Conjugate (ADC) Technology

Antibody-drug conjugates (ADC) are a class of targeted cancer therapies that combine the high specificity of monoclonal antibodies with the potent activity of small molecule cytotoxic drugs to enhance tumor targeting and reduce side effects. Compared to traditional antibodies or antibody fragments, ADCs theoretically have higher efficacy due to their ability to release highly active … Read more

Understanding ADC Drugs: A Visual Guide

by
Understanding ADC Drugs: A Visual Guide

ADC In the era following chemotherapy, targeted therapy, and immunotherapy, ADC drugs, which combine cytotoxic drugs with targeted monoclonal antibodies, have opened a new era of fourth-line cancer treatment with exceptional results. They have become a significant class of new drugs in cancer treatment both domestically and internationally. So, what are ADC drugs (antibody-drug conjugates)? … Read more

Overview of ADC Drug Development Landscape

by
Overview of ADC Drug Development Landscape

Antibody-drug conjugates (ADC) are also known as “biological missiles”. They connect cytotoxic drugs similar to chemotherapy with monoclonal antibodies, consisting of three parts: antibodies, linkers, and payloads (small molecule cytotoxic drugs). This combination achieves the dual advantages of small molecules and antibody drugs, enabling targeted killing of tumors and other diseases. In recent years, global … Read more

Physicochemical Analysis and Structural Characterization of Antibody-Drug Conjugates (ADCs)

by
Physicochemical Analysis and Structural Characterization of Antibody-Drug Conjugates (ADCs)

Preface Preface Author Cloud Assistant Antibody-drug conjugates (ADCs) are a class of emerging drugs that combine the advantages of both antibodies and small molecule toxins. Compared to traditional cytotoxic drugs, ADCs have the advantages of strong targeting and fewer side effects, making them promising in the field of tumor therapy. To date, 11 ADC drugs … Read more

Understanding Antibody-Drug Conjugates (ADC)

by
Understanding Antibody-Drug Conjugates (ADC)

Introduction Antibody-drug conjugates (ADCs) typically consist of: highly specific and high-affinity antibodies, stable linkers, and potent small-molecule cytotoxic drugs1. The key to the development of ADCs lies in the selection of targets, antibodies, cytotoxic payloads, linkers, and the conjugation method. Among these, the conjugation method of ADCs directly determines the drug-to-antibody ratio (DAR), the distribution … Read more

Introduction to Antibody-Drug Conjugates (ADCs)

by
Introduction to Antibody-Drug Conjugates (ADCs)

Antibody-drug conjugates (ADCs) are formed by linking monoclonal antibodies (mAbs) with small molecule drugs through linkers. The specificity of mAbs for tumor cells allows small molecule drugs to act effectively within tumor tissues, significantly reducing the high toxicity and side effects of traditional small molecule drugs while improving overall therapeutic efficiency. Currently, there are 13 … Read more

Introduction to Antibody-Drug Conjugates (ADC)

by
Introduction to Antibody-Drug Conjugates (ADC)

Antibody-drug conjugates (ADCs) are formed by linking monoclonal antibodies (mAbs) with small molecule drugs through linkers. The specificity of mAbs for tumor cells allows small molecule drugs to act effectively within tumor tissues, significantly reducing the high toxic side effects of traditional small molecule drugs and enhancing overall therapeutic efficiency. Currently, there are 13 ADC … Read more